ClinicalTrials.gg
RecruitingNCT073777342026ColECFerSpUpdated Mar 30, 2026

Intrauterine Injection of Type III Collage in FST of EC/AEH

A Phase 2 interventional study of Recombinant Humanized Type III Collagen Lyophilized Fibers + High-dose Progestin and High-dose Progestin in Atypical Endometrial Hyperplasia and Endometrial Cancer, sponsored by Wang Jianliu. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Wang Jianliu · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Endometrial Hyperplasia with a site in China — 14 open to participants now, 15 under way, 5 of them phase 3. Endometrial Hyperplasia · China.

Planned enrollment
14th of 19
30 · median 75
Started
2026
with 3 others
Phase 2
7 of 22
6 open now
Primary completion
2027-12
later than 9 of 14 live
Registered
18th of 22
by date
Lead sponsor
1 of 22
Wang Jianliu

Among the 22 studies in Endometrial Hyperplasia with a site in China, this one is the 14th largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 9 of the 14 other live ones, and was the 18th registered.

Endometrial Hyperplasia

110 studies on the registry are indexed under Endometrial Hyperplasia; 38 are open to participants now.

Browse Endometrial Hyperplasia studies →

Open to participants now

14 of the 22 studies in Endometrial Hyperplasia with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 21 Endometrial Hyperplasia studies recruiting now, 9 (43%) set no upper age limit and 11 (52%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Endometrial Hyperplasia with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if intrauterine injection of "Recombinant Humanized Type III Collagen Lyophilized Fibers" works to treat endometrial cancer or atypical hyperplasia in patients seeking fertility-preserving treatment. It will also learn about the safety of this intervention.The main questions it aims to answer are:

  1. Does the combination of recombinant humanized type III collagen and progestin significantly increase the tumor remission rate at 6 months compared to progestin alone?
  2. What medical problems do participants have when receiving this treatment (e.g., allergic reactions, abnormal inflammatory markers, or histocompatibility issues)? Researchers will compare "recombinant humanized type III collagen plus progestin (experimental group)" to "high-dose progestin alone (control group)" to see if the combination therapy is more effective for fertility preservation.

Participants will:

  1. Take high-dose progestin (such as Medroxyprogesterone Acetate or Megestrol Acetate) orally every day.
  2. If assigned to the experimental group, receive one intrauterine submucosal injection of collagen via hysteroscopy at months 0, 1, and 2, for a total of 3 injections.
  3. Visit the clinic once every 3 months for treatment evaluation and follow-up, which includes hysteroscopic endometrial biopsy, imaging (such as transvaginal ultrasound), and safety tests for relevant biochemical indicators.
03

Conditions studied

  • Atypical Endometrial Hyperplasia
  • Endometrial Cancer
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pathological diagnosis of endometrioid adenocarcinoma (G1 or G2) or atypical endometrial hyperplasia.
  2. For patients with endometrial cancer, magnetic resonance imaging (MRI) or ultrasound must confirm that the lesion is confined to the endometrium or invades less than 1/2 of the myometrium (i.e., FIGO 2009 Stage IA).
  3. Age ≤ 45 years.
  4. Desire to preserve fertility and signed .
  5. No serious medical comorbidities (e.g., severe liver or renal dysfunction).
  6. No to progestin therapy or pregnancy.
  7. No evidence of distant on imaging.

Exclusion criteria

Exclusion Criteria:

  1. Tumor invasion > 1/2 of the myometrium, or FIGO (2009) Stage IB and above.
  2. Tumor differentiation grade G3 or non-endometrioid adenocarcinoma.
  3. Coexistence of other malignant tumors.
  4. to conservative treatment or use of the study drugs.
  5. Known allergy to recombinant protein components.
  6. Acute genital tract inflammation or untreated abnormal vaginal discharge within 2 weeks prior to enrollment.
  7. Previous treatment with high-potency progestin for more than 1 month.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Participants in this arm will receive a combination therapy of oral high-dose progestin and intrauterine injections of Recombinant Humanized Type III Collagen Lyophilized Fibers for fertility preservation

    Drug: Recombinant Humanized Type III Collagen Lyophilized Fibers + High-dose Progestin

  • Active comparator
    Control Group

    Participants in this arm receive the current standard-of-care treatment for fertility preservation in endometrial cancer, which consists of oral high-dose progestin alone. This allows for a direct comparison of efficacy and safety between the progestin-only therapy and the progestin-collagen combination therapy

    Drug: High-dose Progestin

Interventions

  • DrugRecombinant Humanized Type III Collagen Lyophilized Fibers + High-dose Progestin

    Participants in this group will receive a combination therapy. They will take oral high-dose progestin (Medroxyprogesterone Acetate 250mg-500mg/d or Megestrol Acetate 160mg-320mg/d) daily. Additionally, they will receive three intrauterine submucosal injections of Recombinant Humanized Type III Collagen Lyophilized Fibers (50mg per injection) via hysteroscopy at months 0, 1, and 2. Each injection consists of 5ml solution (10mg/ml). The injection is administered at specific sites in the uterine cavity, including the anterior, posterior, left, right, and fundal walls, or surrounding the suspected lesion area.

  • DrugProgestinsStudies of ProgestinsProgestins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants in the control group will receive standard-of-care treatment with oral high-dose progestin alone. The dosage will be Medroxyprogesterone Acetate 250mg-500mg/day or Megestrol Acetate 160mg-320mg/day, taken daily throughout the treatment period

06

What researchers measure

Primary outcomes

  1. 6-month Tumor Complete Remission Rate

    Time frame: 6 months after the start of treatment

Secondary outcomes

  1. Time to Complete Response (CR)

    The duration from the start of treatment to the first documentation of Complete Response (CR), based on negative pathological biopsy and clear imaging findings.

    Time frame: Up to 2 years

  2. 1-Year Recurrence Rate

    The proportion of participants who experience disease recurrence within 12 months after achieving Complete Response. Recurrence is defined as reappearance of cancer evidence in pathology or imaging.

    Time frame: 1 year after CR

  3. Endometrial Thickness and Blood Flow

    Evaluation of endometrial thickness (mm) and blood flow status (via Doppler) assessed by transvaginal ultrasound.

    Time frame: Every 3 months during the 9-month treatment period

  4. 1-Year Pregnancy Rate

    The percentage of participants who achieve clinical pregnancy within one year following the end of treatment.

    Time frame: 1 year after treatment completion

  5. Incidence of Adverse Events (Safety)

    Monitoring for adverse events, including allergic reactions (rash, itching), systemic inflammatory markers (Complete Blood Count, C-Reactive Protein), and organ function (liver and kidney function tests).

    Time frame: Throughout the 9-month treatment period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — General clinical data and fertility-sparing treatment outcomes of patients in both the experimental and control groups will be shared.

Supporting information: Study protocol

Time frame: The data will be available within 6 months after the publication of the primary research paper.

Access criteria: Researchers interested in obtaining the clinical and treatment data can apply by contacting the principal investigator.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 30, 2026
StartActual
Jan 30, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 30, 2029
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07377734
Lead sponsor
Wang Jianliu
Responsible party
Wang Jianliu (Professor, Peking University People's Hospital) — Sponsor-investigator
First posted
Jan 30, 2026
Start date
Jan 30, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Mar 30, 2026

Study contacts

Yiqin Wang
Contact
emily_wang92@163.com
+86-15201277651

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion